Skip to content
2000
Volume 12, Issue 3
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Transition metal complexes with terpyridine ligands have attracted a widespread interest with respect to biomedical applications: [(tpy)PtCl]Cl and [(tpy)RuCl3] are potent anti-tumor agents with activities comparable to those of cisplatin and carboplatin. The RuII complexes feature a high potential as reactive probes for DNA oxidation; whereas, luminescent IrIII, PtII or EuIII complexes have been utilized in biolabeling applications. Besides complexes based on heavy second or third row transition metal ions, remarkable results have been obtained with respect to the development of new types of metallodrugs, based on the naturally more abundant and intrinsically less toxic first row transition metal ions (e.g. FeII, CuI/II, ZnII). The perspective of these complexes in particular with respect to future biomedical applications in chemotherapy and cleavage of nucleic acids is evaluated in this review.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/156802612799078919
2012-02-01
2025-05-11
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/156802612799078919
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test